Given the intimate relationship between bone and bone marrow, we hypothesized that the human bone marrow may function as a source (or reservoir) of bone-forming progenitor cells. We observed a population of cells within the bone marrow which produce bone-specific or bone-related proteins. The production of these proteins was developmentally regulated in human long-term bone marrow cell cultures; the bone proteinproducing cells (BPPC) are observed under serum-free, shortterm culture conditions, respond to bone-related and not hematopoietic growth factors, and are derived from a population of low-density, nonadherent, MylO-negative (or low MylO density), marrow cells (MylO is an antigen found on most hematopoietic progenitor cells). Cultivation of marrow-derived BPPC in secondary, serum-containing cultures results in their differentiation into osteoblastlike cells. At this stage of development, BPPC produce an extracellular matrix which incorporates both bone-related proteins and radiolabeled calcium. Human bone marrow BPPC thus represent a newly described cell phenotype important to both bone and hematopoietic cell biology. (J. Clin. Invest. 1990Invest. . 86:1387Invest. -1395
Introduction
The hematopoietic microenvironment influences the growth and differentiation of hematopoietic cells. Although poorly understood, this microenvironment is comprised of soluble regulatory factors, cellular elements, and extracellular components. Soluble factor production within this microenvironment is restricted to the stromal.cells (1, 2) . Such cells are defined as nonhematopoietic components of bone marrow, e.g., connective tissue, vascular, or neural elements. In longterm bone marrow cultures the maintenance of hematopoiesis is dependent upon the establishment of an intact layer of adherent (stromal) cells. Such adherent cell layers elaborate soluble factors and deposit extracellular matrix which, in turn, influence hematopoietic proliferation and differentiation (1, 3) .
Presented in part to the American Society of Hematology, 1989. Little information is available concerning the intimate relationship between the bone marrow and its surrounding tissue: the bone. The available data demonstrate that bone marrow stromal cells respond to bone growth factors in vitro (increasing the numbers of alkaline phosphatase-positive cells) (4, 5) , that stromal cells (or stromal cell lines) generate osteoid in vivo (6, 7) , and that cells of osteoclastic potential are found in the marrow (vide infra). However, these studies do not establish the lineage derivation and/or hierarchy of such cells.
Similarly, the few studies on bone formation address only its indirect relation to bone marrow development, showing that bone formation in in vivo models is followed by marrow formation (8) (9) (10) . Additionally, either type of in vitro model shows limited degrees of bone formation, if any. In particular, the use of postfetal mesenchymal tissue to generate bone progenitor cells results in chrondrogenesis but is often inadequate for osteogenesis (1 1). Thus, information concerning the cellular activation signals and intracellular processing during bone formation is limited.
One of the central issues concerning bone formation regards the developmental lineages of the bone cell types, namely the osteoblast and the osteoclast. There is adequate evidence to suggest that osteoblasts arise from mesenchymal cell populations and that osteoclasts are derived from bloodborn monocyte/macrophage cells. Fischman and Hay first demonstrated that monocytes fused to form osteoclasts in regenerating newt limbs (12) . Although the role of macrophage fusion remains controversial (4, 13), further evidence for the blood-born origin of the osteoclast was pioneered by LeDouarin using a chick:quail chimera in which nuclear morphology allows clear distinction of cell derivation. These studies conclusively demonstrated that osteoblasts and osteocytes are derived from the limb bud mesenchyma, whereas osteoclasts arise from blood-born hematopoietic cells (14, 15) . The importance of these observations was subsequently shown by the successful cure of osteopetrosis utilizing bone marrow transplantation in both animals (16) and humans (17) . While such data conclusively show the hematogenous origin of osteoclasts, little knowledge exists on the nature or location of the stem cell population(s) capable of differentiating into bone-forming osteoblasts.
A number of proteins, isolated from demineralized bone, are involved in bone formation. Osteonectin (ON)' is a 32-kD protein which binds calcium, hydroxyapatite, and collagen, and thus may initiate nucleation of the mineral phase of bone deposition (18) . Cellular localization of osteonectin message reveals its presence in a variety of developing tissues (19) . However, it is present in its highest levels in bones of the axial skeleton, skull, and the blood platelet (megakaryocyte) (20) .
Bone y-carboxy glutamic acid-containing protein (BGP, osteocalcin) is a vitamin K-dependent, 5,700-D calcium binding bone protein which is specific for bone and may regulate Ca2" deposition ( 18, 21) .
We utilized monoclonal antibodies to bone-related proteins (22, 23) as phenotypic probes of the hematopoietic microenvironment. We report that bone proteins are produced in human long-term bone marrow cell cultures, and that the marrow-derived cells producing bone proteins proliferate in response to regulators of bone development but not hematopoietic growth factors. Finally, marrow-derived bone proteinproducing cells are capable of osteoblastlike differentiation.
Methods
Marrow cell preparation and culture. Human bone marrow aspirates were obtained from normal volunteers after informed consent. Longterm bone marrow cultures (LTBMC) were established exactly as described by Kaplan and Gartner (24) . For immunolocalization, two to three coverslips were placed in each LTBMC culture and removed weekly for immunocytochemistry (see below).
For short-term (7-d) assays, human bone marrow cells were subjected to density and adherence separation techniques as described previously (25, 26 Radioimmunoassay and immunochemistry. Bone antigen expression was determined by solid-phase RIA as we have described elsewhere (25, 27) using monoclonal antibodies to human bone-related proteins: osteonectin, BGP, and SAOS2-P80, all at 10 ug/ml. Bone-related protein antibodies (22, 28) were localized by immunoperoxidase cytochemistry utilizing an avidin-biotin system previously described by this laboratory (27, 29) .
'5Calcium incorporation into extracellular matrix. BPPC were cultivated under serum-free conditions, and serum-stimulated on day 7 Fig. 3 ), cells pelleted by centrifugation, and 4(Ca2+ incorporation into the trypsin/EDTA extractable ECM determined by scintillation counting. Trypsin-resistant ECM was removed by Triton X-100 extraction as described previously (30, 31) and counted similarly.
Results and Discussion
Expression of bone proteins in human long-term marrow cultures. Human LTBMC were examined for the production of the bone-related proteins: ON, BGP, and for SAOS2-P80, a membrane-specific antigen present on cells of the human osteosarcoma cell line SAOS2 (23 hematopoietic colonies in parallel as controls. These data indicated a 74±15% reduction of CFU-GM in the presence of antibody and complement versus complement only (n = 3 separated donors, each condition cultivated in triplicate). Whereas hematopoietic cells were reduced, BPPC were not effected by anti-MY 10 treatment. Indeed, the data suggests that an inhibitory cell may be removed by MY-10 depletion (Table I) .
Alternatively, we depleted MY 10-positive cells by immunoadherence (to anti-IgG coated petri dishes). These data corroborated the cytotoxicity data, in that the MY 10+ cells failed to grow under the same serum-free conditions which support the proliferation of BPPC (not shown). We believe that both of these studies suggest that BPPC evolve from MY 10-negative cells. However, we interpret these observations with some caution as neither are conclusive. quantitative data on bone protein expression, we also examined serum-free, short-term human bone marrow cultures for SAOS2-P80, osteonectin, and BGP production, utilizing a solid-phase radioimmunoassay (SPRIA) developed in this laboratory (27) . Examination of unstimulated input marrow cells indicates that ON and BGP are not detected by RIA, whereas low amounts ofthe SAOS2-P80 antigen are seen (Fig. 3 A) . Cultivation of (unstimulated) marrow cells under serum-free conditions results in increased surface expression on ON, BGP, and SAOS2-P80 among adherent cells. These data confirm and extend our immunocytochemical data by showing that adherent BPPC constitutively express bone proteins within the hematopoietic microenvironment. Importantly, they also are the first to show the expression of SAOS2- P80 in nontransformed cells, and suggest that this antigen may be developmentally regulated during osteopoiesis. Whether a single cell population coexpresses each of these antigens or multiple bone protein-producing lineages exist remains to be determined. Nonetheless, the RIA data are consistent with immunocytochemical observations. Growth factor responsiveness of bone protein producing cells. TGF-(3 is the prototype of a family of multifunctional regulatory peptides with diverse effects on cellular function (33, 34) . Importantly, it is a negative modulator of hematopoietic cell proliferation which is produced by hematopoietic (and other) cells, blood platelets being the most concentrated source of TGF-# in the body (33) . Moreover, TGF-fP is found in high quantity in bone, suggesting that bone contains the greatest total amount of TGF-fi (34, 35) . TGF-# stimulates cartilage formation, is synthesized and secreted in bone cell cultures, (Fig. 3 B) . Conversely, BPPC were not affected by the recombinant hematopoietic growth factors: interleukins-1,3, or 6 nor GM-CSF (Table II) . Thus, the increase in BPPC numbers in stimulated adherent cell populations shows that TGF-/# is an important modulator of bone protein expression within the hematopoietic microenvironment, and their lack of hematopoietic factor responsiveness further distinguishes them from hematopoietic progenitor cells. Osteoblastlike differentiation ofmarrow-derived bone protein producing cells. Further documentation of the osteal nature of BPPC was observed after the addition of serum to 7-d-old serum-free cultures. Serum repletion stimulated BPPC to differentiate into large osteoblastlike cells (Fig. 4 A) . These cells morphologically resemble marrow-derived osteoblasts (36), having abundant, foamy cytoplasm and a single, eccentric nucleus. Immunocytochemical analysis revealed that these cells continue to express low amounts of cytoplasmic bone-related protein (ON; BGP; SAOS2-P80, and a2 HS-GP), and, importantly, deposit bone-related proteins in the extracellular matrix (ECM) (Fig. 4, B and C) . A macrophage phenotype was ruled out as these cells fail to express (either constitutively or TGF-# stimulated) the MO-1 antigen, (which is found on granulocytes, monocytes, and tissue macrophages [37] ) and are nonspecific esterase and NBT-reductase negative. Finally, immunocytochemical studies indicate that these cells express type I and type III collagen (not shown) further confirming both their osteal nature and ruling out a macrophage phenotype as these collagens are not expressed by macrophages.
The extracellular deposition of bone-related proteins suggests that these cells are organizing the ECM in an osteogenic fashion, i.e., bone protein is incorporated into the matrix antecedent to, or coincident with mineralization. Consistent with this hypothesis, the ECM surrounding these cells is positive for the von Kossa reaction (Fig. 4 D) , which detects the presence of calcium phosphates in mineralized tissue (38) . Further, these cells deposit radiolabeled calcium (45Ca24) into the ECM, showing a 10-100-fold increase in incorporation over 8 d of culture (Table III) . . ; . X . . . . Fig. 3 ), cells pelleted by centrifugation, and 45Ca++ incorporation into the trypsin/EDTA extractable ECM determined by scintillation counting. Trypsin-resistant ECM was removed by Triton X-100 extraction as described previously (30, 31) and counted similarly. Total extractable counts on day 3 were determined using a single Triton X-100 extract. NT, not tested.
In summary, these culture systems document the presence of a new marrow cell phenotype capable of elaborating bonerelated proteins, osteoblastlike differentiation, and bonelike organization of the ECM. In LTBMC, which are replete with serum and contain heterogeneous cell populations, BPPC are developmentally regulated, and regionally restricted in their distribution. In short-term, serum-free cultures, these cells evolve from NALD input cells as an adherent cell phenotype with a limited capacity to proliferate but which nonetheless express bone-related proteins, and respond to TGF-#t with a marked increase in proliferation. Subsequently, these cells respond to undefined serum factor(s) with osteoblastlike differentiation and matrix deposition. The nature ofthe serum regulator(s) is unknown, but it is not mimicked by the addition of TGF-,3 or 1,25-OH vitamin D3 to serum-free cultures (not shown).
Our that organ cultures of murine marrow, or marrow stromal cells, have bone-forming potential both in vivo (using diffusion chambers) and in vitro (7, 40, 41) . These investigators further identified an osteogenic cell phenotype in a subpopulation of adherent bone marrow fibroblasts, localized near the (endosteal) bone surface (40, 42) . These cells are the progeny of fibroblast colony-forming cells (CFC-F) which are serumresponsive, generate heterogeneous populations of cells, and are strongly adherent (43) (44) (45) (46) . In sharp contrast, our observations of human BPPC show that these putative osteoprogenitor cells are nonadherent (i.e., are not found among adherent stromal cells), proliferate under serum-free conditions, are nonresponsive to hematopoietic regulators, but do respond to bone-related growth factors (Fig. 5) . Human BPPC also develop under temperature conditions which are restrictive to CFC-F proliferation (330C vs. 370C, respectively), (47) . Finally, human cells producing bone proteins lack distinct fibroblast characteristics being morphologically similar to (pre)osteoblasts. Whether a relationship exists between BPPC and cells ofother lineages such as fibroblasts will require coanalysis (Fig. 5) . Whereas this hypothesis remains to be proven, marrow-derived BPPC nonetheless provide a valuable model for studies on the regulation of bone protein production in health and disease.
